ISU Abxis Co., Ltd. (KOSDAQ:086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,190.00
-130.00 (-2.44%)
At close: Apr 18, 2025, 3:30 PM KST
-28.31%
Market Cap 193.39B
Revenue (ttm) 60.26B
Net Income (ttm) 14.72B
Shares Out 36.91M
EPS (ttm) n/a
PE Ratio 13.14
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 172,147
Average Volume 116,911
Open 5,180.00
Previous Close 5,320.00
Day's Range 5,030.00 - 5,220.00
52-Week Range 3,945.00 - 8,000.00
Beta 0.70
RSI 53.50
Earnings Date Mar 13, 2025

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 95
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

In 2024, ISU Abxis's revenue was 60.26 billion, an increase of 10.96% compared to the previous year's 54.31 billion. Earnings were 14.72 billion, an increase of 307.63%.

Financial Statements

News

There is no news available yet.